CureMetrix vs Viz.ai
These two never land on the same shortlist. CureMetrix sells mammography software and Viz.ai sells a stroke, vascular and cardiac alerting platform. Breast imaging centers reading screening exams are cmAngio's market. It quantifies breast arterial calcification and has FDA decisions for V1.0 (October 2023), V1.6 (April 2025) and V2.0 (July 2026), and the older cmTriage scoring product was cleared in 2019. The AUC of 0.98 to 0.992 and the 400-plus US sites are CureMetrix's own figures. Neither vendor publishes a price. Viz.ai suits a stroke center coordinating transfers: ContaCT received the De Novo for large vessel occlusion triage on CTA, and openFDA lists 12 Viz.ai records, two of them De Novo. A 2025 meta-analysis of 12 studies and 15,595 patients found shorter door-to-groin and door-in-door-out times at such centers, with no significant difference in clinical outcomes.
Radiology · Reviewed November 2, 2026
CureMetrix
by CureMetrix
AI for mammograms: cmAngio quantifies breast arterial calcification (FDA-cleared), cmTriage prioritizes screening exams.
Viz.ai
by Viz.ai · founded 2016
Care coordination platform with FDA-cleared imaging AI for stroke, vascular and cardiac conditions.
When to pick each one
CureMetrix
- cmAngio reads breast arterial calcification on screening mammograms
- cmAngio V2.0 cleared by FDA, July 2026
- Validation reported on Hologic and GE platforms
Viz.ai
- Alerts for LVO, hemorrhage, PE and aortic disease
- ContaCT received an FDA De Novo for LVO triage, 2018
- SOC 2 Type II and ISO 27001 listed
Score
Each row shows points earned of points available under the published rubric.
CureMetrix
48of 100
Viz.ai
89of 100
| Dimension | CureMetrix | Viz.ai | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 10 / 10 | -10 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 18.2 / 18.2 | -5.5 |
| RCT / meta-analysis / systematic review | 3.9 / 7.8 | 7.8 / 7.8 | -3.9 |
| Funding & adoption signal | 3 / 12 | 12 / 12 | -9 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 6 / 6 | -6 |
Scroll horizontally to see every column.
Pricing
CureMetrix
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. The homepage shows none. |
Viz.ai
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Sold to health systems after a demo request. |
Evidence
CureMetrix
FDA decisions
K260980 (opens in new tab)510(k)2026-07-30
cmAngio V2.0
K250754 (opens in new tab)510(k)2025-04-10
cmAngio V1.6
K232367 (opens in new tab)510(k)2023-10-05
cmAngio V1.0
K183285 (opens in new tab)510(k)2019-03-08
cmTriage
Peer-reviewed
3 PubMed records name CureMetrix.
- A Novel Breast Arterial Calcification Age-Based Percentile Nomogram for the Incremental Prediction of Incidental Cardiovascular Events. (opens in new tab)
- Evaluation of an Artificial Intelligence System for Detection of Invasive Lobular Carcinoma on Digital Mammography. (opens in new tab)
- Multicenter, Multivendor Validation of an FDA-approved Algorithm for Mammography Triage. (opens in new tab)
Viz.ai
FDA decisions
K250354 (opens in new tab)510(k)2025-06-10
Viz Subdural+
K232363 (opens in new tab)510(k)2024-02-05
Viz HDS, Viz Volume Plus, Viz ICH+
DEN230003 (opens in new tab)De Novo2023-08-03
Viz HCM
K223443 (opens in new tab)510(k)2023-03-17
Viz AAA
K223042 (opens in new tab)510(k)2022-10-21
Viz LVO (ContaCT)
Show 7 more
K221100 (opens in new tab)510(k)2022-08-29
Viz RV/LV
K220439 (opens in new tab)510(k)2022-07-25
Viz SDH
K213319 (opens in new tab)510(k)2022-02-18
Viz ANEURYSM
K210209 (opens in new tab)510(k)2021-03-23
Viz ICH
K193658 (opens in new tab)510(k)2020-03-18
Viz ICH
K180161 (opens in new tab)510(k)2018-04-20
Viz CTP
DEN170073 (opens in new tab)De Novo2018-02-13
ContaCT
Peer-reviewed
5 PubMed records name Viz.ai.
- Automated Emergent Large Vessel Occlusion Detection Using Viz.ai Software and Its Impact on Stroke Workflow Metrics and Patient Outcomes in Stroke Centers: A Systematic Review and Meta-analysis. (opens in new tab)
- Revolutionizing Intracranial Hemorrhage Diagnosis: A Retrospective Analytical Study of Viz.ai ICH for Enhanced Diagnostic Accuracy. (opens in new tab)
- Real-world evaluation of the accuracy of the Viz.AI automated intracranial hemorrhage volume calculation tool. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | CureMetrix | Viz.ai |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | 2016 |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.